Get the Stockscreener App
2.24
2.61%
-0.06
After Hours:
2.26
0.02
+0.89%
Veru Inc stock is traded at $2.24, with a volume of 44,652.
It is down -2.61% in the last 24 hours and down -1.32% over the past month.
Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases. Its drug development program consists of two late-stage new chemical entities, enobosarm and sabizabulin. Enobosarm, an oral selective androgen receptor modulator, is being developed to make weight reduction by GLP-1 RA drugs more tissue selective for loss of fat and preservation of lean mass, and is planned for a Phase 2b PLATEAU clinical study in obesity. Sabizabulin, an oral microtubule disruptor, is being developed for the treatment of inflammation in atherosclerotic cardiovascular disease to lower high-sensitivity CRP in patients with stable coronary artery disease, with a planned Phase 2 study.
See More
Previous Close:
$2.30
Open:
$2.31
24h Volume:
44,652
Relative Volume:
0.31
Market Cap:
$35.95M
Revenue:
$6.66M
Net Income/Loss:
$-25.52M
P/E Ratio:
-1.8512
EPS:
-1.21
Net Cash Flow:
$-28.98M
1W Performance:
+0.00%
1M Performance:
-1.32%
6M Performance:
-29.34%
1Y Performance:
-59.27%
1-Day Range:
$2.22
$2.3827
1-Week Range:
$2.21
$2.50
52-Week Range:
$2.10
$7.40
Veru Inc Stock (VERU) Company Profile
Name
Veru Inc
Sector
Industry
Phone
(312) 595-9123
Address
2916 N. MIAMI AVENUE, MIAMI, FL
Compare VERU vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
VERU
Veru Inc
|
2.24 | 36.92M | 6.66M | -25.52M | -28.98M | -1.21 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Veru Inc Stock (VERU) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Canaccord Genuity | Buy |
| May-14-24 | Initiated | B. Riley Securities | Buy |
| Mar-28-24 | Initiated | Raymond James | Outperform |
| Jun-07-23 | Upgrade | Jefferies | Underperform → Hold |
| Apr-13-21 | Initiated | Jefferies | Buy |
| Feb-09-21 | Reiterated | H.C. Wainwright | Buy |
| Jan-21-20 | Reiterated | H.C. Wainwright | Buy |
| Mar-20-19 | Initiated | Oppenheimer | Outperform |
| Jul-03-18 | Initiated | Maxim Group | Buy |
View All
Veru Inc Stock (VERU) Latest News
Veru outlines new Phase IIb obesity trial and targets interim analysis in Q1 2027 while increasing cash reserves - MSN
Veru Inc. (NASDAQ: VERU) Q1 2026 earnings call transcript - MSN
Veru Inc. (NASDAQ:VERU) Q1 2026 Earnings Call Transcript - Insider Monkey
Veru Q1 2026 Earnings Call Transcript - MarketBeat
Veru Inc. Charts Risky but Clearer Post-GLP-1 Path - TipRanks
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Veru Inc. (VERU) Advances Clinical Pipeline with Enobosarm and S - GuruFocus
Veru Inc (VERU) Q1 2026 Earnings Call Highlights: Strategic Adva - GuruFocus
VERU INC. SEC 10-Q Report - TradingView
VERU: No revenue, $5.3M net loss, $33M cash, strategic shift to drug development, going concern risk - TradingView
Veru (VERU) Q1 2026 Earnings Call Transcript - The Globe and Mail
VERU: Net loss narrowed, cash reserves rose, and enobosarm advances with FDA support for new trials - TradingView
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts - Investing.com
Earnings call transcript: Veru Inc. Q1 2026 sees stock rise amid strategic shifts By Investing.com - Investing.com India
Veru reports Q1 EPS (26c) vs. (61c) last year - TipRanks
VERU INC (NASDAQ:VERU) Reports Narrower-Than-Expected Q1 Loss, Highlights Key Clinical Trial Timeline - ChartMill
Veru Inc. Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress - TradingView
VERU: Q1 net loss narrowed, cash rose, and new enobosarm/semaglutide trial to launch soon - TradingView
Veru (NASDAQ: VERU) narrows loss as enobosarm obesity program advances - Stock Titan
Veru Inc. Advances Phase 2b PLATEAU Clinical Trial of Enobosarm and Semaglutide for Weight Management in Older Adults with Obesity - Quiver Quantitative
Veru tests enobosarm to help older semaglutide users beat weight-loss plateau - Stock Titan
A Look at Veru's Upcoming Earnings Report - Benzinga
Veru Inc. (VERU.US) is scheduled to release its earnings report before the market opens on February 11. - 富途牛牛
Veru (VERU) Price Target Increased by 11.11% to 25.50 - Nasdaq
Veru Inc. to Host Conference Call for Fiscal 2026 First Quarter Financial Results and Business Update - Quiver Quantitative
Biopharma Veru sets Feb. 11 webcast on Q1 2026 results - Stock Titan
Published on: 2026-02-01 18:16:35 - baoquankhu1.vn
Wall Street Recap: Is Veru Inc a defensive stockJuly 2025 PostEarnings & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
Block Trades: Will Veru Inc benefit from AI trends2025 Major Catalysts & Intraday High Probability Setup Alerts - baoquankhu1.vn
Analyzing Verano (OTCMKTS:VRNOF) & Veru (NASDAQ:VERU) - Defense World
Growth Report: Will Veru Inc benefit from AI trends2025 Buyback Activity & Fast Momentum Entry Tips - baoquankhu1.vn
Veru prices 1.4M shares at $3.00 in underwritten public offering - MSN
Targets Report: Will Veru Inc stock attract ESG investors2025 Market Sentiment & Real-Time Volume Analysis - Bộ Nội Vụ
What Investors Should Know About a $1.5 Million Apogee Insider Sale Amid a 60% Stock Rally - AOL.com
Is Veru Inc. stock a buy in volatile marketsJuly 2025 Final Week & Trade Opportunity Analysis - Улправда
Why Veru Inc. (FMW) stock trades below fair valueTrade Entry Report & Fast Entry High Yield Tips - ulpravda.ru
Is Veru Inc. stock attractive after correction2025 Macro Impact & Entry Point Confirmation Alerts - ulpravda.ru
ulpravda> 2026> How dovish Fed policy supports Veru Inc. (FMW) stockTake Profit & High Conviction Buy Zone Picks - ulpravda.ru
Why Veru Inc. (FMW) stock remains stableProfit Target & Low Risk High Reward Ideas - Улправда
Aug Drivers: Why Veru Inc. (FMW) stock remains stable2025 Stock Rankings & Risk Controlled Stock Alerts - ulpravda.ru
About UsGreat American Insurance GroupSpecialty Property & Casualty Insurance - FinancialContent
Veru Inc.Common Stock (NQ: VERU - FinancialContent
Why Vera Therapeutics Stock Zoomed Higher Today - AOL.com
Is Veru Inc. (FMW) stock prepared for digital transitionWeekly Market Report & Daily Entry Point Trade Alerts - ulpravda.ru
User | poteaudailynews.comVeru Inc.Common Stock (Nasdaq:VERU) Stock Quote - FinancialContent
What Makes Veru Inc. (VERU) a Strong Momentum Stock: Buy Now? - MSN
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Veru (NASDAQ:VERU) Share Price Crosses Below Two Hundred Day Moving Average – What’s Next? - Defense World
Veru outlines 72-week Phase IIb PLATEAU study targeting obesity plateau population following FDA guidance - MSN
Veru Inc | 4: Statement of changes in beneficial ownership of securities-Director Hyun Grace - 富途牛牛
Veru Inc. (NASDAQ:VERU) Q4 2025 Earnings Call Transcript - Insider Monkey
Veru Inc Stock (VERU) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):